{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:06:19Z","timestamp":1794607579952,"version":"4.9.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.vaccine.2020.09.061","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T17:56:15Z","timestamp":1600797375000},"page":"7533-7541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement"],"prefix":"10.1016","volume":"38","author":[{"given":"Wen-Hsiang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurodh Shankar","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Algaissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-Hung","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Pollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Strych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Bottazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8770-1042","authenticated-orcid":false,"given":"Peter J.","family":"Hotez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lustigman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanying","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Te K.","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.09.061_b0005","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(03)14630-2","article-title":"Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003","volume":"362","author":"Zhong","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.09.061_b0010","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa030747","article-title":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome","volume":"348","author":"Drosten","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.09.061_b0015","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa030781","article-title":"A novel coronavirus associated with severe acute respiratory syndrome","volume":"348","author":"Ksiazek","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.09.061_b0020","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.09.061_b0025","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV \u2013 a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2020.09.061_b0030","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nri1732","article-title":"Immunopathogenesis of coronavirus infections: implications for SARS","volume":"5","author":"Perlman","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2020.09.061_b0035","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.09.061_b0040","doi-asserted-by":"crossref","first-page":"12672","DOI":"10.1128\/JVI.78.22.12672-12676.2004","article-title":"Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets","volume":"78","author":"Weingartl","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.09.061_b0045","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.vaccine.2005.01.033","article-title":"Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets","volume":"23","author":"Czub","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.061_b0050","article-title":"Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI","volume":"4","author":"Liu","year":"2019","journal-title":"Insight"},{"key":"10.1016\/j.vaccine.2020.09.061_b0055","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","article-title":"Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV","volume":"181","author":"Yasui","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.09.061_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/2965cfae-b77d-4014-8b7b-236e01a35492","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2020.09.061_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.micinf.2020.04.005","article-title":"The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement","author":"Hotez","year":"2020","journal-title":"Microbes Infect"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2020.09.061_b0070","first-page":"31","article-title":"SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement","volume":"18","author":"Jaume","year":"2012","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.vaccine.2020.09.061_b0075","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acsinfecdis.6b00006","article-title":"Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates","volume":"2","author":"Wang","year":"2016","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.vaccine.2020.09.061_b0080","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1074\/jbc.C300520200","article-title":"A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2","volume":"279","author":"Wong","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.09.061_b0085","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1586\/erv.12.126","article-title":"Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome","volume":"11","author":"Jiang","year":"2012","journal-title":"Expert Review of Vaccines"},{"key":"10.1016\/j.vaccine.2020.09.061_b0090","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.virol.2009.07.018","article-title":"Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity","volume":"393","author":"Du","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.09.061_b0095","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/vim.2009.0090","article-title":"A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity","volume":"23","author":"Du","year":"2010","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2020.09.061_b0100","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.bbrc.2009.05.003","article-title":"Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells","volume":"384","author":"Du","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2020.09.061_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2006.10.031","article-title":"Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model","volume":"25","author":"Du","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.061_b0110","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.4049\/jimmunol.174.8.4908","article-title":"Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies","volume":"174","author":"He","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.09.061_b0115","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.4049\/jimmunol.176.10.6085","article-title":"Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein","volume":"176","author":"He","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.09.061_b0120","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/hv.27464","article-title":"Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate","volume":"10","author":"Chen","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.09.061_b0125","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.xphs.2017.04.037","article-title":"Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate","volume":"106","author":"Chen","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2020.09.061_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0030005","article-title":"A mouse-adapted SARS-coronavirus causes disease and mortality in BALB\/c mice","volume":"3","author":"Roberts","year":"2007","journal-title":"PLoS pathogens"},{"key":"10.1016\/j.vaccine.2020.09.061_b0135","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/JVI.02980-14","article-title":"Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology","volume":"89","author":"Honda-Okubo","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.09.061_b0140","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1128\/JVI.01702-06","article-title":"Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor","volume":"81","author":"Tseng","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.09.061_b0145","first-page":"249","article-title":"MF59: A Safe and Potent Adjuvant for Human Use","volume":"13","author":"Kommareddy","year":"2017"},{"key":"10.1016\/j.vaccine.2020.09.061_b0150","doi-asserted-by":"crossref","unstructured":"Gar\u00e7on N, Friede M. 6 - Evolution of Adjuvants Across the Centuries. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin's Vaccines (Seventh Edition): Elsevier; 2018. p. 61-74.e4.","DOI":"10.1016\/B978-0-323-35761-6.00006-7"},{"key":"10.1016\/j.vaccine.2020.09.061_b0155","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1136\/bmj.321.7271.1237","article-title":"The importance of injecting vaccines into muscle. Different patients need different needle sizes","volume":"321","author":"Zuckerman","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2020.09.061_b0160","unstructured":"Center_for_Disease_Control_and_Prevention. Administer the vaccine(s)."},{"key":"10.1016\/j.vaccine.2020.09.061_b0165","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3201\/eid1107.050219","article-title":"SARS vaccine development","volume":"11","author":"Jiang","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2020.09.061_b0170","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1016\/j.vaccine.2006.10.031","article-title":"Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model","volume":"25","author":"Du","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.061_b0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jaut.2012.07.004","article-title":"The role of Th17\/IL-17 on eosinophilic inflammation","volume":"40","author":"Dias","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.vaccine.2020.09.061_b0180","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.immuni.2015.07.010","article-title":"Stop Press: Eosinophils Drafted to Join the Th17 Team","volume":"43","author":"Keely","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2020.09.061_b0185","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1128\/IAI.72.8.4410-4415.2004","article-title":"Analysis of serum cytokines in patients with severe acute respiratory syndrome","volume":"72","author":"Zhang","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.09.061_b0190","unstructured":"Clinicaltrials.gov. Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) (TOCIVID-19). (2000, Mar. 19-). 2020."},{"key":"10.1016\/j.vaccine.2020.09.061_b0195","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","article-title":"Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus","volume":"12","author":"Agrawal","year":"2016","journal-title":"Hum Vaccin Immunother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20312329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20312329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:47:33Z","timestamp":1759402053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20312329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":39,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0264410X20312329"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.061","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.15.098079","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}